Clinical analysis of EBRT vs TLM in the treatment of early (T1-T2N0) glottic laryngeal cancer

Shen, Jing; Hu, Ke; Ma, Jiabin; Zhen, Hongnan; Guan, Hui; Wang, Wenhui; Zhang, Fuquan

doi:10.7150/jca.46487

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(22):6686-6694. doi:10.7150/jca.46487 This issue Cite

Research Paper

Clinical analysis of EBRT vs TLM in the treatment of early (T1-T2N0) glottic laryngeal cancer

Jing Shen, Ke Hu^✉, Jiabin Ma, Hongnan Zhen, Hui Guan, Wenhui Wang, Fuquan Zhang

Chinese Academy of Medical Sciences & Peking Union Medical College, NO.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing 100730, People's Republic of China

Citation:

Shen J, Hu K, Ma J, Zhen H, Guan H, Wang W, Zhang F. Clinical analysis of EBRT vs TLM in the treatment of early (T1-T2N0) glottic laryngeal cancer. J Cancer 2020; 11(22):6686-6694. doi:10.7150/jca.46487. https://www.jcancer.org/v11p6686.htm

Other styles

Abstract

Objective: To analyze the clinical efficacy of external beam radiation therapy (EBRT) vs transoral laser microsurgery (TLM) in patients with early glottic laryngeal carcinoma (T1-T2N0) and the effect of treatment choice on vocal function.

Methods: A retrospective analysis of patients with T1-T2N0 glottic laryngeal carcinoma who underwent EBRT or TLM between January 2012 and December 2018 in PUMCH. The Kaplan-Meier method was used to analyze local control, progression-free survival and overall survival, and the VHI-30 scale was used to evaluate the effects of EBRT and TLM on vocal function.

Results: A total of 185 patients, all with pathologically confirmed squamous cell carcinoma, were enrolled. The median age was 62 years (38-88). N0 disease was confirmed by imaging: 142/185 (76.76%) patients had T1N0 disease, and 43/185 patients (23.24%) had T2/N0 disease. A total of 91/195 (49.19%) patients received an EBRT dose of 66-70 Gy/30-35f, at 2.0-2.3 Gy/f. 94/185 (50.81%) patients received TLM. The median follow-up time was 42 months (12-92), and the 3-year LC, PFS, and OS rates for the EBRT and TLM groups were 96.9% vs 94.1%(p=0.750), 95.3% vs 93.1%(p=0.993) and 93.3% vs 95.4%(p=0.467), respectively. The VHI-30 scales were used at the baseline showed no significant difference between the two groups 19.20±3.324 vs 21.65±9.80 (p=0.250), but the EBRT group had a low voice handicap after treatment, 10.24±6.093 vs 19.45±5.112 (p=0.001) (6 months) and 9.45±5.112 vs 14.97±7.741 (12 months). No CTCAE grade 3 or above side effects were observed in the EBRT group, but 3 cases of vocal cord stenosis were observed in the TLM group.

Conclusion: The application of EBRT for early glottic laryngeal carcinoma (T1-T2N0) had an obvious curative effect with high LC and OS rates, no serious side effects, and a low voice handicap rate.

Keywords: glottic laryngeal cancer, external beam radiation therapy, transoral laser microsurgery, voice outcome, VHI

Citation styles

APA

Shen, J., Hu, K., Ma, J., Zhen, H., Guan, H., Wang, W., Zhang, F. (2020). Clinical analysis of EBRT vs TLM in the treatment of early (T1-T2N0) glottic laryngeal cancer. Journal of Cancer, 11(22), 6686-6694. https://doi.org/10.7150/jca.46487.

ACS

Shen, J.; Hu, K.; Ma, J.; Zhen, H.; Guan, H.; Wang, W.; Zhang, F. Clinical analysis of EBRT vs TLM in the treatment of early (T1-T2N0) glottic laryngeal cancer. J. Cancer 2020, 11 (22), 6686-6694. DOI: 10.7150/jca.46487.

NLM

CSE

Shen J, Hu K, Ma J, Zhen H, Guan H, Wang W, Zhang F. 2020. Clinical analysis of EBRT vs TLM in the treatment of early (T1-T2N0) glottic laryngeal cancer. J Cancer. 11(22):6686-6694.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.